AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company
focused on treating iron deficiency anemia and developing novel imaging
agents to aid in the diagnosis of cancer and cardiovascular disease,
today announced that Ricardo Zayas has been appointed Senior Vice
President of Operations. Mr. Zayas brings over two decades of
pharmaceutical operations and commercial manufacturing experience to the
Company. In his new position with AMAG, Mr. Zayas will be responsible
for leading the Company’s manufacturing, materials management, quality
assurance, quality control, and supply chain functions and will report
directly to Brian J.G. Pereira, MD, President and CEO.
“Ricardo’s extensive pharmaceutical manufacturing experience will be
invaluable as we prepare to launch and commercialize Feraheme™
(ferumoxytol injection),” commented Dr. Pereira. “Ricardo has
successfully led manufacturing organizations for several large
pharmaceutical companies and has a proven track record of working
closely and successfully with government agencies including the FDA. The
addition of Ricardo further strengthens our management team as we
continue our transition to a commercial biopharmaceutical company.”
Prior to joining AMAG, Mr. Zayas was Vice President and General Manager
of Operations at Wyeth Pharmaceuticals in Puerto Rico since 2007, where
he was responsible for pharmaceutical product manufacturing operations,
with more than 900 employees. Additionally, Mr. Zayas participated in
the development of a greenfield vaccine and biotech manufacturing
facility in Puerto Rico. Before joining Wyeth, Mr. Zayas spent more than
five years at Schering-Plough Corporation in Puerto Rico as General
Manager of Operations and Manufacturing, where he was responsible for
four separate facilities, including a pharmaceutical manufacturing
facility and a chemical manufacturing facility. Earlier in his career
Mr. Zayas was with Warner Lambert, where he held positions of increasing
responsibility in operations, including managing the oral contraceptive
manufacturing facility in Puerto Rico. Mr. Zayas received his B.S. in
industrial engineering from Kansas State University.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat anemia and novel imaging agents to
aid in the diagnosis of cancer and cardiovascular disease.
Feraheme ™ (ferumoxytol injection) is being developed for use as
an intravenous iron replacement therapeutic agent for the treatment of
iron deficiency anemia and as a diagnostic agent for vascular-enhanced
magnetic resonance imaging to assess peripheral arterial disease.
AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362
